Catalent close to settlement with Elliott over board seats, Reuters reports

Catalent is near reaching a resolution with Elliott Investment Management that would result in a shake-up of the U.S. contract drug manufacturer’s board of directors after its share price lost half of its value in the past year, Reuters’ Svea Herbst-Bayliss and Maggie Fick report. The company is slated to agreed to add four new directors proposed by Elliott to its board, the authors say, citing people familiar with the situation.